The augmentation of tumor-specific immunity by virus help. III: enhanced generation of tumor-specific Lyt-1+2-T cells is reponsible for augmented tumor immunity in vivo
Yoshioka, T.; Fukuzawa, M.; Takai, Y.; Wakamiya, N.; Ueda, S.; Kato, S.; Fujiwara, H.; Hamaoka, T.
Cancer Immunology and ImmunoTherapy 21(3): 193-198
1986
ISSN/ISBN: 0340-7004 Accession: 078226332
PDF emailed within 1 workday: $29.90
Related References
Yoshioka, T.; Fukuzawa, M.; Takai, Y.; Wakamiya, N.; Ueda, S.; Kato, S.; Fujiwara, H.; Hamaoka, T. 1986: The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo Cancer Immunology Immunotherapy: Cii 21(3): 193-198Shimizu, Y.; Fujiwara, H.; Ueda, S.; Wakamiya, N.; Kato, S.; Hamaoka, T. 1984: The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells European Journal of Immunology 14(9): 839-843
Ting, C.C.; Rodrigues, D.; Nordan, R. 1982: Studies of the mechanisms for the induction of in vivo tumor immunity. VI. Induction of specific and nonspecific cell-mediated immunity in tumor-bearing hosts and its correlation with transplantation tumor immunity Cellular Immunology 66(1): 45-58
Sano, S.; Izumi, Y.; Sugihara, S.; Nakajima, H.; Fujiwara, H.; Hamaoka, T. 1987: The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens Cancer Immunology Immunotherapy: Cii 25(2): 105-110
Hamaoka, T.; Takai, Y.; Kosugi, A.; Mizushima, Y.; Shima, J.; Kusama, T.; Fujiwara, H. 1985: The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (M-DP) derivatives. I: Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity Cancer Immunology and ImmunoTherapy 20(3): 183-188
Hamaoka, T.; Takai, Y.; Kosugi, A.; Mizushima, Y.; Shima, J.; Kusama, T.; Fujiwara, H. 1985: The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity Cancer Immunology Immunotherapy: Cii 20(3): 183-188
Fujiwara, H.; Hamaoka, T. 1988: Cellular mechanisms of tumor rejection in vivo and enhanced induction of anti tumor protective immunity applicable to tumor-specific immunotherapy Progress in Experimental Tumor Research 32: 69-103
Okayasu, T. 1981: Augmentation of specific anti-tumor immunity by immunization with xenogenized tumor cells and its application to the experimental cancer treatment Hokkaido Journal of Medical Science 56(6): 615-622
Makidono, R. 1996: A mechanism involved in augmentation of anti-tumor immunity by irradiation to the tumor: tumor irradiation promoted generation of CD4+helper T cells against a murine immunogenic tumor Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica 56(8): 575-578
Sano, H.; Kosugi, A.; Sano, S.; Fujiwara, H.; Hamaoka, T. 1987: The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity Cancer Immunology Immunotherapy: Cii 25(3): 180-184
Ang, W.K.; De Graaf, T.; Hui, K.M. 1996: Study of genes involved in the generation of tumor-specific immunity in mice following the injection of H-2K-b-transformed tumor cells FASEB Journal 10(6): A1466
Zarling, J.M.; Tevethia, S.S. 1973: Transplantation immunity to simian virus 40-transformed cells in tumor-bearing mice. I. Development of cellular immunity to simian virus 40 tumor-specific transplantation antigens during tumorigenesis by transplanted cells Journal of the National Cancer Institute 50(1): 137-147
Fujiwara, H.; Fukuzawa, M.; Yoshioka, T.; Nakajima, H.; Hamaoka, T. 1984: The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I: Lyt-1+2- T cells do not necessarily require recruitment of Hosts cytotoxic T cell precursors for implementation of in vivo immunity The Journal of Immunology (1950) 133(3): 1671-1676
Fujiwara, H.; Fukuzawa, M.; Yoshioka, T.; Nakajima, H.; Hamaoka, T. 1984: The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity Journal of Immunology 133(3): 1671-1676
Cohen, A.M. 1973: Host immunity to growing sarcomas: tumor-specific serum inhibition of tumor-specific cellular immunity Cancer 31(1): 81-89
Fujiwara, H.; Shimizu, Y.; Takai, Y.; Wakamiya, N.; Ueda, S.; Kato, S.; Hamaoka, T. 1984: The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses European Journal of Immunology 14(2): 171-175
Kawakita, M.; Rao, G.; Ritchey, J.K.; Ornstein, D.K.; Hudson, M'liss A.; Ratliff, T.L.; Tartaglia, J.; Paoletti, E. 1996: Canary-pox virus-mediated cytokine gene therapy induces tumor specific and non-specific immunity against mouse prostate tumor Journal of Urology 155(5 Suppl): 516A
Ratliff, T.L.; Kawakita, M.; Tartaglia, J.; Paoletti, E. 1996: Canary-pox (ALVAC) virus-mediated cytokine gene therapy induces tumor specific and non-specific immunity against mouse prostate tumor Acta Urologica Belgica 64(2): 85
Kodama, M.; Yamagishi, H.; Hashimoto, I.; Pellis, N.R.; Kahan, B.D. 1980: Comparison of specific tumor immunity induced with irradiated tumor cells and solubilized tumor antigen Journal of Kyoto Prefectural University of Medicine 89(5): 325-336
Udono, H.; Levey, D.L.; Srivastava, P.K. 1994: Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo Proceedings of the National Academy of Sciences of the United States of America 91(8): 3077-3081